Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era.

Eur Respir Rev · 2018 · PMC9488842 · PMID 29653948

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

likely to be significantno p-value reported

Although these pre-clinical data are promising, there are likely to be significant challenges in translating BMPR2 gene therapy to humans with our current limitations in vector delivery to the pulmonary endothelium, immunogenicity and uncertainty regarding whether increasing BMPR-II expression results in sustainable long-term improvements in PAH.

also in 1,824 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.